Researchers from the University of British Columbia and Vancouver Coastal Health Research Institute have found that a widely prescribed drug for multiple sclerosis (MS) is associated with longer survival for patients.
Mar 18, 2019
0
438
A European clinical trial involving some 3,200 people has been launched to test four possible experimental treatments against the coronavirus.
Mar 22, 2020
0
311
Drugs called interferon betas are common treatments for multiple sclerosis (MS), reducing relapses and slowing motor function decline. Interferon beta, a protein known to contain a zinc binding pocket, is thought to reduce ...
Aug 10, 2022
0
56
The human heart is particularly vulnerable to viruses. That's because cardiac myocytes, the heart muscle cells that give your heart its ability to "beat," have one major weakness – they don't reproduce themselves to repair ...
Sep 29, 2017
0
36
A new study led by investigators at Brigham and Women's Hospital (BWH) reports the discovery of a genetic variant that is associated with a patient's likelihood of responding to interferon-beta, one of the medications used ...
May 14, 2015
0
93
Scientists at The University of Nottingham have discovered a molecular mechanism which could bring about the development of new treatments for Multiple Sclerosis (MS) -- a chronic inflammatory disease of the central nervous ...
Jun 21, 2011
1
0
A newfound genetic regulatory mechanism may shape the immune system's ability to fight viral infections, and play a key role in autoimmune diseases that occur when immune cells attack bodily tissues.
Nov 27, 2018
0
112
Scientists from the University of Southampton and Synairgen, a respiratory drug development company spun out from the University, can announce positive data from its Phase II clinical trial, into the effectiveness of the ...
Apr 19, 2012
0
0
Pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG), the German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed fingolimod (trade name: Gilenya), a drug for the treatment ...
Jul 6, 2015
0
11
The immunosuppressive drug fingolimod (trade name: Gilenya) was approved for an expanded therapeutic indication in May 2014: It is now also available for adults with highly active relapsing remitting multiple sclerosis (RRMS) ...
Oct 10, 2014
0
0
